Federal Register of Legislation - Australian Government

Primary content

PB 58 of 2011 Determinations/Health as made
This Determination amends the National Health (Price and Special Patient Contribution) Determination 2010 (No. PB 109 of 2010) to change all references to Medicare Australia CEO to Chief Executive Medicare and also changes the amount of the claimed price for three brands of pharmaceutical items, inserts one brand and omits three brands of pharmaceutical items.
Administered by: Health
Registered 29 Aug 2011
Tabling HistoryDate
Tabled HR12-Sep-2011
Tabled Senate12-Sep-2011
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

PB 58 of 2011

National Health (Price and Special Patient Contribution) Amendment Determination 2011 (No. 6)1

National Health Act 1953

I, FELICITY McNEILL, Acting First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Determination under section 85B of the National Health Act 1953.

Dated 26 August 2011

 

 

 

 

 

 

 

FELICITY McNEILL

Acting First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing


 


1          Name of Instrument

            (1)        This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2011 (No. 6).

            (2)        This Instrument may also be cited as PB 58 of 2011.

2          Commencement

            This Instrument commences on 1 September 2011.  

3          Amendment of the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)

            Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).



Schedule 1     Amendments

 

[1]       Paragraph 7(1)(c)

omit:

Medicare Australia CEO

substitute:

Chief Executive Medicare

[2]       Schedule 1, entry for Alendronic Acid in the form Tablet 70 mg (as alendronate sodium)

omit from the column headed “Claimed Price”:                          28.46     substitute:             29.10

[3]       Schedule 1, after entry for Alendronic Acid

insert:

Alendronic acid with colecalciferol

Tablet equivalent to 70 mg (as alendronate sodium) with 140 micrograms colecalciferol

Oral

Fosamax Plus 70 mg/140 mcg

4

34.24

36.74

[4]       Schedule 1, omit entry for Bromocriptine

[5]       Schedule 1, entry for Doxycycline

substitute:

Doxycycline

Capsule 100 mg (as hydrochloride) (containing enteric coated pellets)

Oral

Doryx

7

1.69

2.64

 

 

Oral

Doryx

21

5.04

6.76

 

Tablet 50 mg (as hydrochloride)

Oral

Vibra-Tabs

25

3.01

4.05

 

Capsule 50 mg (as hydrochloride) (containing enteric coated pellets)

Oral

Doryx

25

3.01

4.09

[6]       Schedule 1, entry for Mirtazapine in the form Tablet 30 mg

omit from the column headed “Claimed Price”:                          19.84     substitute:             20.32

 

[7]       Schedule 1, entry for Mirtazapine in the form Tablet 45 mg

omit from the column headed “Claimed Price”:                          31.57     substitute:             32.12

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.  See http://www.frli.gov.au.